|
Astragaloside IV enhances Paclitaxel chemosensitivity in breast cancer cells via regulating Nrf-2 signaling
|
T. Runwei   , L. Chaoran , Z. Yinghui |
| Breast Surgery Department, Jiading Maternal and Child Health Hospital, Shanghai, China , postop.tsin@foxmail.com |
|
|
Abstract: (13 Views) |
Background: Chemotherapy resistance has become a problem for the treatment of breast cancer patients. This study aimed to investigate whether astragaloside IV (AS-IV) has synergistic effects to enhance Paclitaxel (PTX) chemosensitivity in breast cancer cells. Materials and Methods: CCK-8 assays were performed to evaluate the sensitivity of the cell to AS-IV and PTX. The flow cytometric analysis of Annexin-V-fluoresceine isothiocyanate (FITC)/propidium iodide (PI) staining was carried out to evaluate cell apoptosis. The western blotting assay was used to measure the apoptosis-related proteins and Nrf-2 levels. ROS levels were measured using Dichlorofluorescein (DCF) assay. Results: AS-IV enhances PTX chemosensitivity in MDA-MB-231 and MCF-7 cells by enhancing the inhibitory effect of cell viability and promotion effect on cell apoptosis of PTX. The synergistic effects of AS-IV to PTX could decrease the Nrf-2 expression and increase the ROS levels. Nrf-2 signaling was related to ROS generation. Conclusion: AS-IV may enhance PTX chemosensitivity in breast cancer via regulating Nrf-2 signaling. AS-IV might be used as a potential adjuvant drug to increase PTX sensitivity in breast cancer cells. |
|
| Keywords: Astragaloside IV, breast cancer, chemosensitivity, nuclear factor erythroid 2-related factor 2, reactive oxygen species. |
|
|
Full-Text [PDF 1258 kb]
(5 Downloads)
|
|
Type of Study: Original Research |
Subject:
Radiation Biology
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
